We are a global immunotherapy powerhouse aspiring to translate science into survival

Our mission

We are committed to improving the health of people worldwide with our fundamental research and development of immunotherapies and mRNA vaccines. We believe in scientific rigor, innovation and passion as a driving force. BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence.

BioNTainer: a novel solution for mRNA manufacturing

Learn more about the manufacturing facility we’re building in Melbourne

There are no events to display at the moment.

BioNTech research and development (R&D) laboratory

Learn more

Therapeutic areas & priority programs

Oncology

We have built a unique oncology portfolio consisting of three complementary therapeutic modalities: mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies. We believe that each of these modalities has the potential to offer precise mechanisms for targeting cancer cells.

And we want to go further: We continue to execute our combination strategy, aiming to develop new therapies based on synergistic modalities, ultimately creating space for curative approaches. We have identified priority programs to achieve our aim of addressing the full continuum of cancer – from resected cancers in the adjuvant setting to later-stage advanced and metastatic cancers.

Our next-generation immunomodulator BNT327

We believe that this bispecific antibody candidate has the potential to become a next-generation immuno-oncology backbone suitable for a broad range of cancers. BNT327 binds to both PD-L1 and VEGF-A and thus acts on two validated biological mechanisms against cancer in a synergistic manner. Additionally, BNT327’s binding directly positions the therapy candidate where it is needed: in the tumor microenvironment.

Learn more

Our mRNA cancer immunotherapies

Our mRNA cancer immunotherapy approach aims at inducing immune responses against cancer targets that are either individual for each patient or shared by patients with the same tumor type. We believe that our individualized mRNA cancer immunotherapy candidates are particularly suited for early intervention in the adjuvant setting, after surgery or chemotherapy, where they can address residual tumor cells and potentially prevent disease recurrence.

Learn more

Infectious diseases

We believe the technology behind our COVID-19 vaccine has potential against a range of other infectious diseases. Our COVID-19 vaccine efforts have demonstrated several advantages over the traditional vaccine development that we aim to translate into new mRNA vaccine programs targeting infectious diseases with a massive health burden.

Learn more

Pipeline

We strive to exploit the full potential of the body’s immune system by combining powerful new therapeutic modalities and a diverse array of biological targets to successfully help address cancer, infectious diseases and other serious diseases.

Novel-novel combination trials

Explore more

2.1

bn €

Investment into R&D in 2025 to address cancer care

Explore more

Phase 2 and phase 3 clinical trials in oncology

Explore more

Join us and become part of our team!

We are always on the lookout for dedicated and curious new talents supporting our team of visionaries. Join us and be part of our unique pioneering spirit.

Browse our open positions

Connect with us

Questions about our products, services or clinical trials? Find the right contact person at our Service Center.

Reach out

Stay up to date

Looking for latest news, events or SEC filings?
Sign-up for our alerts here.

Scientific publications

We continue to drive future innovation through sharing key findings in a peer reviewed format.

Discover

Acknowledgement of Country

We acknowledge Traditional Owners of Country throughout Australia and recognise their continuing connection to lands, waters and communities. We pay our respects to all Aboriginal and Torres Strait Islander cultures; and to Elders past and present.